knowledge -WSS

knowledge

author：explore 2025-09-09 05:35:26 - browse：3129

Microsoft's head of research Peter Lee speaking at STAT Breakthrough Summit in San Francisco. Sarah Gonzalez for STAT

SAN FRANCISCO — Surging interest in generative AI among medical professionals since ChatGPT’s launch is perhaps a testament to its potential — but it could also lead clinicians, and patients to experiment with it before there is wider consensus on how to navigate its biases and other pitfalls, Microsoft’s head of research Peter Lee said Thursday at STAT’s Breakthrough Summit.

About a month after OpenAI — Microsoft has a significant financial stake in the company — launched its chatbot in 2022 on November 30, which happened to be Lee’s birthday, he got a note from a doctor friend who said he’d used it so his receptionist could file after-visit summaries for patients. While Lee and a handful of other doctors at Microsoft had been impressed with the GPT-4’s capabilities, they knew it had weaknesses.

“The emotions were really mixed. I mean we were thrilled,” he said, but then “just within minutes there’s a feeling of dread. We had already come to the realization that GPT-4 would be prone to issues, issues of bias, hallucination, mathematical and logical errors,” he said. “And so, there’s an immediate question: ‘Should we allow this to happen?’”

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Duchenne breakthrough therapy leaves behind pioneering families
Next article： The lessons of Aduhelm, an Alzheimer's drug that was not to be

Wikipedia

focus

WSS

Do digital therapeutics have a future in medicine?

Time to name cancers by genetics, not organ of origin, expert says

Commercial surrogacy can be ethical, despite pope’s claims

Biden administration opens offers in Medicare drug price negotiations

Legitimacy of 'customer' in Supreme Court gay rights case raises ethical, legal flags

Kremlin open to talks over potential prisoner swap involving detained US reporter Evan Gershkovich

hotspot

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

entertainment

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

What we need to know about Arena Bioworks

Virginia high school admissions case could be legal follow

Woodcock on FDA’s accelerated approval and her next chapter

After affirmative action ruling, medical educators look to 'holistic review'

Russians and Belarusians back at Wimbledon as war in Ukraine continues

George Santos makes 1st court appearance after pleading not guilty to 13 counts

The Democratic Party promised to overhaul its primaries. Doing that has been anything but simple

Cancer drug shortages should be causing more outrage

3 killed, 8 injured in late

hotspot

Woodcock on FDA’s accelerated approval and her next chapter

Apple Vision Pro: A first look at health apps on the new VR headset

Cognito secures funding to test medical device for Alzheimer's

Elon Musk announces 'temporary limits' for reading Twitter posts

ThunderShirts, dance parties and anxiety meds can help ease dogs' July Fourth dread

Cognito secures funding to test medical device for Alzheimer's

entertainment

Wikipedia

focus

focus